Lesson · 3 min read · MOTS-c
MOTS-c: native peptide, analog, and trial limits
Native MOTS-c and CB4211 are different
MOTS-c is a 16-amino-acid mitochondrial-derived peptide. CB4211 is an engineered analog developed by CohBar. Results for CB4211 do not establish the effects or safety of native-sequence MOTS-c.
Native MOTS-c experiments reported metabolic effects in mice. A human exercise study measured naturally occurring MOTS-c in ten healthy young men. Those participants did not receive MOTS-c treatment.
What the human records describe
CohBar reported a randomized, placebo-controlled CB4211 study. Its Phase 1b portion used daily subcutaneous treatment for four weeks in 20 adults with obesity and nonalcoholic fatty liver disease. The sponsor reported exploratory biomarker changes. This was a short analog study, not proof of native MOTS-c treatment benefits.
NCT07505745 separately lists a planned placebo-controlled study of investigational MOTS-c in adults with prediabetes and overweight or obesity. Its public record describes daily subcutaneous treatment for 12 weeks but does not disclose the amount. No results are posted. Registration does not verify that the planned treatment was delivered or effective.
Approval and access are separate
MOTS-c has no FDA-approved drug product. An October 2026 HHS interim policy describes conditional compounding enforcement discretion for MOTS-c acetate by subcutaneous or intramuscular routes. Its Federal Register notice calls the policy a nonbinding draft. This does not establish a validated human regimen.
What a clinician-directed record needs
The sources here do not validate a native MOTS-c treatment schedule. If your clinician has supplied a plan, record whether the material is native-sequence MOTS-c or a named analog, its salt form, formulation, concentration, prescribed amount and unit, route, timing, and duration. The record also needs the indication, dispensing source, outcome measures, follow-up date, and clinician-supplied stopping instructions. Neither an analog trial nor a registry schedule can fill in missing details.
Quick check
Which record establishes a validated native MOTS-c treatment regimen?
Sources
- Lee et al., 2015: MOTS-c metabolic experiments in mice
- Reynolds et al., 2021: Endogenous MOTS-c response to exercise in humans
- CohBar 2021 Form 10-K: CB4211 is a MOTS-c analog
- ClinicalTrials.gov NCT03998514: CB4211 Phase 1a/1b study
- CohBar, August 10, 2021: CB4211 Phase 1a/1b topline results
- ClinicalTrials.gov NCT07505745: Planned MOTS-c study in prediabetes, no posted results
- FDA evaluation dated May 11, 2026: MOTS-c free base and acetate for the July 2026 PCAC meeting
- HHS, October 2026: Conditional 503A peptide compounding policy, MOTS-c acetate in Appendix B
- Federal Register, October 30, 2026: Notice of HHS draft peptide enforcement policy
Peptiday editorial summary, not clinically reviewed, November 6, 2026. For education only, not medical advice. Talk to a clinician before starting, stopping or changing treatment.